Macugen
(Pegaptanib sodium)ApprovedSmall molecule
Pegaptanib sodium is used to treat a type of vision loss caused by wet age-related macular degeneration, a disease where abnormal blood vessels grow under the retina and damage central vision in older adults.[2] Macugen is currently approved and in use across 4 indications[4].[1]
Macugen is one of 23 small molecule programs targeting Wet Macular Degeneration. It is currently in Approved.
4
Indications
20
Total Trials
0
Active Trials
22
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
16 competitors in Macular Degeneration
#DrugCompanyPhaseTrials
1Vabysmo
RocheApproved
Macugen
BBausch Health Americas, Inc.
Approved
Copaxone
TevaApproved
Iheezo
BB. Braun Medical Inc.
Approved
Avastin
RochePhase 3
Visudyne
BBausch Health Americas, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
OTX-TKI
OOcular Therapeutix, Inc.
Phase 3
Tiespectus
EEyeBiotech Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration6 trials
Diabetic Macular Edema2 trials
Safety and Efficacy2 trials
Retinal Vein Occlusion2 trials
7 more indications
Wet Age-Related Macular Degeneration1 trial
Cystoid Macular Edema1 trial
Neovascular AMD1 trial
DME1 trial
Cataract1 trial
Regulatory
FDA Approval Timeline[5]
Dec 17, 2004
MACUGEN
NDA NDA021756
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Macugen drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pegaptanib sodium. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Vascular Endothelial Growth Factor a Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.